UBS Initiates Solid Biosciences at Buy With $20 Price Target

H.C. Wainwright reiterated a Buy rating and $25 price target for Solid Biosciences (SLDB), citing EU orphan designation for its gene therapy SGT-212. The stock is down 9.2% over the past week, trading at $5.81. Analysts have revised earnings upwards, with a consensus Strong Buy rating. The company reported progress in its pipeline and a potential $200M stock offering.

Solid Biosciences (SLDB) received EU Orphan Drug Designation for SGT-212, a gene therapy for Friedreich's ataxia. The Phase 1b FALCON trial has dosed five participants with no serious adverse events. SGT-212 has also received U.S. FDA designations. SLDB stock is currently at $5.83, down 1.52%.

Solid Biosciences (SLDB) received EU orphan designation for SGT-212, a gene therapy for Friedreich’s ataxia. The company reported no serious adverse events in its Phase 1b trial with five participants. Initial data is expected in Q1 2027. SGT-212 also has U.S. Fast Track and Orphan Drug designations.

INPEX, TotalEnergies, and Woodside Energy began FEED work for the Bonaparte CCS project in Australia. INPEX will increase its stake to 74%. The project could store 443 million tons of CO2, with first injection targeted for the early 2030s, pending approvals. The Ichthys Joint Venture may be the primary client, reducing its LNG emissions by 40%.

Toyota reported a 2.2% drop in global sales to 860,107 vehicles and a 3.2% decline in production to 889,079 vehicles in September, marking three consecutive months of decreases. Declines were driven by a 19.7% drop in China and a 29.8% slump in the Middle East, while sales rose 1.8% in Japan and 8.4% in the US. Production fell 18.6% in China and 2.9% in the US, but increased 5.8% in Japan.

First Solar (FSLR) opened the first phase of its $330M facility in South Carolina, onshoring production for its Series 6 Plus modules. The facility supports the company's solar panel manufacturing.